Avalo Therapeutics, Inc.
NCM: AVTXLive Quote
📈 ZcoreAI Score
Our AI model analyzes Avalo Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get AVTX Z-Score →About Avalo Therapeutics, Inc.
Healthcare
Biotechnology
Avalo Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development of therapies for the treatment of immune dysregulation in the Unites States. Its lead asset includes AVTX-009, a humanized monoclonal antibody that binds to interleukin-1ß, which is in phase 2 clinical trial to treat inflammatory diseases. The company was formerly known as Cerecor Inc. and changed its name to Avalo Therapeutics, Inc. in August 2021. Avalo Therapeutics, Inc. was incorporated in 2011 and is headquartered in Rockville, Maryland.
📊 Fundamental Analysis
Avalo Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -69.3% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -72.4%, which indicates that capital utilization is currently under pressure.
At a current price of $13.66, AVTX currently sits at the 59th percentile of its 52-week range (Range: $3.39 - $20.72).
🏥 Financial Health
🔴
Profit Margin
Weak
⚠️
Debt/Equity
Moderate
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
⚠️
Beta (Risk)
Moderate Volatility
Key Financials
Market Cap
$311.29M
Trailing P/E
--
Forward P/E
-4.50
Beta (5Y)
0.94
52W High
$20.72
52W Low
$3.39
Avg Volume
641K
Day High
Day Low